Comparison of Amphotericin B, Flucytosine, and Voriconazole with Amphotericin B and Flucytosine in the Treatment of Cryptococcal Meningitis in AIDS

沈银忠,卢洪洲,齐唐凯,江雪艳,张仁芳,郑毓芳,刘莉,王江蓉
DOI: https://doi.org/10.3969/j.issn.1673-3827.2009.06.005
2009-01-01
Abstract:Objective To compare the efficacy and safety of amphotericin B combimed with flucytosine and voriconazole in initial treatment of AIDS patients with cryptococcal meningitis,and to evaulate the value of voriconazole for the treatment of cryptococcal meningitis in AIDS.Methods Twenty patients with HIV-associated cryptococcal meningitis received initial treatment: triple therapy with amphotericin B(0.5 mg/kg daily),flucytosine(100 mg/kg daily),and intravenous voriconazole(6 mg/kg every 12 hours for the first 24 hours then 4 mg/kg every 12 hours)(study group,n=10);amphotericin B plus flucytosine(control group,n=10).Reduction rate of yeast counts in cerebrospinal fluid(CSF),resolution of clinical symptoms,fatality rate and side effects were compared between the two groups.Results Reduction rate of yeast counts in CSF with triple therapy including amphotericin B,flucytosine and voriconazole was significantly higher than that with amphotericin B plus flucytosine treatment(0.743 vervus 0.408,P=0.009).There were significant differences between the study group and the control group in the mean time of alleviation or resolution of headache(12 days vervus 20 days,P=0.009).There were no differences between the two groups in the prevalence of adverse effects and mortality at 2,4,8 or 12 weeks after treatment.Conclusions Triple therapy with amphotericin B,flucytosine plus voriconazole could effectively reduce Cryptococcus neoformans counts in CSF.It is an alternative for cryptococcal meningitis in AIDS.
What problem does this paper attempt to address?